# Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma

> **NCT07371611** · PHASE3 · RECRUITING · sponsor: **Qunxing Li,MD** · enrollment: 104 (estimated)

## Conditions studied

- Locally Advanced Oral Squamous Cell Carcinoma
- Oral Squamous Cell Carcinoma (OSCC)

## Interventions

- **DRUG:** Sintilimab plus nab-paclitaxel and platinum-based chemotherapy
- **PROCEDURE:** Radical surgery combined with radiotherapy or chemoradiotherapy

## Key facts

- **NCT ID:** NCT07371611
- **Lead sponsor:** Qunxing Li,MD
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2030-12-31
- **Final completion:** 2033-12-31
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07371611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07371611, "Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07371611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*